首页> 外文期刊>Journal of cardiovascular pharmacology and therapeutics >Comparison of Efficacy between Ramipril and Carvedilol on Limiting the Expansion of Abdominal Aortic Aneurysm in Mouse Model
【24h】

Comparison of Efficacy between Ramipril and Carvedilol on Limiting the Expansion of Abdominal Aortic Aneurysm in Mouse Model

机译:ramipril与卡维地洛之间的疗效比较限制小鼠模型中腹主动脉瘤的扩张

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: Abdominal aortic aneurysm (AAA) is a common condition that may be life-threatening when it is unrecognized. The aim of this study is to evaluate and compare the efficacy of ramipril and carvedilol on limiting AAA expansion in mouse model. Methods and Results: A total of 36 experimental AAA mouse model was induced with the continuous infusion of angiotensin II (Ang II) in 20-week-old male apolipoprotein E-deficient mice. They were randomly divided into 3 treatment groups and fed orally for 8 weeks; saline alone, ramipril (2.5 mg/30g/d), or carvedilol (3.125 mg/30g/d), respectively. Aortic diameter (AD) was measured by micro-computed tomography, and the level of biomarkers of aortic tissue such as monocyte chemoattractant protein-1 (MCP-1) and tissue inhibitor matrix metalloproteinase-1 (TIMP-1) was evaluated. After treatment, AD of both ramipril and carvedilol group was smaller than in the saline group. The percentage change of AD in both ramipril and carvedilol groups was significantly smaller than that of the saline group. Pathologic examination revealed relatively well-preserved aortic walls in the ramipril group compared to the carvedilol and saline groups. The level of MCP-1 was markedly decreased in both the ramipril and carvedilol groups compared to the saline group. The level of TIMP-1 was higher in the carvedilol group when compared to either the saline or ramipril groups. Conclusions: Ramipril and carvedilol treatment shows similar efficacy in limiting AAA expansion in mouse model. Future clinical research would be warranted to validate these results.
机译:目的:腹主动脉瘤(AAA)是一种常见的条件,当它无法识别时可能是危及生命的。本研究的目的是评估和比较Ramipril和Carvedilol对鼠标模型中AAA扩张的效果。方法和结果:在20周龄戊蛋白E缺陷小鼠中,共诱导36种实验性AAA小鼠模型II(Ang II)的连续输注。它们随机分为3种治疗组,口服喂食8周;单独盐水,ramipril(2.5mg / 30g / d),或卡维地洛(3.125mg / 30g / d)。通过微计算断层扫描测量主动脉直径(AD),评价主动脉组织如单核细胞化学蛋白-1(MCP-1)和组织抑制剂基质金属蛋白酶-1(TIMP-1)的模拟器的生物标志物水平。治疗后,Ramipril和Carvedilol组的AD小于盐碱组。 Ramipril和Carvedilol组中的广告的百分比变化显着小于盐碱组的变化。病理检查与卡维洛尔和盐水组相比,在Ramipril组中显示出相对良好的保持主动脉壁。与盐水组相比,ramipril和卡维地洛醇组中MCP-1的水平显着降低。与盐水或ramipRil组相比,Carvedilol组的TIMP-1水平较高。结论:Ramipril和Carvedilol治疗表明了在小鼠模型中限制AAA扩张的相似效果。未来的临床研究将有保证验证这些结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号